CPLX2

Across TCGA pan-cancer cohorts, CPLX2 Mutation is linked to patient survival in 3 of 34 cancer types, making it a survival-associated CPLX2 data layer compared with 21 for mass-spec protein and 3 for mass-spec protein.

The strongest signal is observed in ovarian serous cystadenocarcinoma (OV), where higher CPLX2 Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated CPLX2 expression acts as an unfavorable survival marker.

OV, PRAD, and ESCA are the cancer types where CPLX2 Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
OV	OS	Median	II,III,IV	0.311	0.691	.042	12	view →
PRAD	DFS	Median	All	0.085	0.774	<.001	6	view →
ESCA	OS	Median	II,III,IV	0.216	0.702	.014	6	view →

Pink = unfavorable, green = favorable. Showing the 3 strongest of 3 lineages.

CPLX2–OV (OS)

Open the OV breakdown →